Clinical trials: Schizophrenia(Acute)
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Schizophrenia
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia
This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic…
- Trial name
- NCT05168007
- Testing
- WID-RGC20(Cariprazine) 3mg/day, WID-RGC20(Cariprazine) 6mg/day
- Where
- South Korea
- Volunteers
- 342 people
- Sponsor
- Whanin Pharmaceutical Company
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
The primary objective of this randomized trial was to investigate whether early initiation of treatment with Risperdal Consta after an acute episode was not inferior to the routine approach (oral treatment for 12 weeks followed…
- Trial name
- NCT00216671
- Testing
- early initiation of treatment with Risperdal Consta, routine initiation of treatment with Risperdal Consta
- Where
- 31 sites in Denmark, Finland and 8 more
- Volunteers
- 220 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00615433
- Testing
- Lurasidone, Olanzapine, Lurasidone 40 mg tablets
- Where
- 52 sites in United States, Colombia and 3 more
- Volunteers
- 478 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
F17464 in Acute Schizophrenia Trial
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia.
- Trial name
- FAST (NCT02151656)
- Testing
- F17464
- Where
- 27 sites in France, Hungary and 3 more
- Volunteers
- 158 people
- Sponsor
- Pierre Fabre Medicament
Schizophrenia
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
- Trial name
- NCT00080327
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
The purpose of this study was to evaluate the efficacy and safety of elpipodect at a range of doses (8 mg, 16 mg, and 24 mg once daily [QD]) in adult participants who have an acute episode of schizophrenia according to Diagnostic…
- Trial name
- NCT04624243
- Testing
- Elpipodect, Risperidone
- Where
- 121 sites in United States, Bulgaria and 10 more
- Volunteers
- 499 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia.
- Trial name
- NCT02109562
- Testing
- RBP-7000, Risperidone
- Where
- 32 sites in United States
- Volunteers
- 354 people
- Sponsor
- Indivior Inc.
SCHIZOPHRENIA 1 (Disorder)
Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults
This is a Phase 3, randomized, double-blind, parallel-group, active- and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic with a…
- Trial name
- NCT07911787
- Testing
- HS-10380, Aripiprazole
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms
- Trial name
- NCT00645229
- Testing
- Ziprasidone
- Where
- Portugal
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia…
- Trial name
- NCT01541371
- Testing
- Paliperidone ER
- Volunteers
- 405 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Acute Schizophrenia
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia
- Trial name
- NCT05325645
- Testing
- OPC-34712FUM/ Brexpiprazole fumarate
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Acute Schizophrenia
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
This is a non-Inferiority trial to evaluate efficacy and safety of hydrochloride carliprazine capsules and aripiprazole tablets in treating acute schizophrenia in Chinese adults.
- Trial name
- NCT06589817
- Testing
- Hydrochloride Carliprazine capsules, Aripiprazole tablets
- Volunteers
- 376 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Schizophrenia
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients
The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients
- Trial name
- NCT00645372
- Testing
- Risperidone, Ziprasidone
- Where
- 5 sites in China
- Volunteers
- 242 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156104
- Testing
- Asenapine, Haloperidol
- Volunteers
- 460 people
- Sponsor
- Organon and Co